Tom Brady’s Next Chapter: Teaming Up With eMed to Expand GLP-1 Access for the American Workforce

Tom Brady is swapping the football field for the health insurance field, in a sense. The retired quarterback now serves as chief wellness officer at eMed, a digital health company working to connect more American workers with GLP-1 weight loss medications.

Brady joined eMed CEO Linda Yaccarino for a conversation on Fox Business’s The Claman Countdown, where they outlined the plan. The strategy skips traditional consumer advertising entirely. Instead, it targets employers directly, since most working Americans get their health coverage through their jobs.

Brady didn’t hold back when describing the scope of the problem. He called obesity a nationwide crisis. He wants the partnership to expand wellness access on a scale the country hasn’t seen before.

So how do these GLP-1 medications actually work? Drugs like semaglutide and tirzepatide copy a hormone your gut already produces naturally. This hormone slows digestion, extends feelings of fullness, and helps regulate insulin levels in the body.

The FDA has approved certain formulations for treating type 2 diabetes. Other versions carry approval for long-term weight management, though only for patients who meet specific BMI criteria. Doctors must prescribe every one of these drugs, and patients need ongoing medical supervision throughout treatment.

That requirement explains why the employer strategy makes practical sense. Yaccarino noted that more than 60% of Americans get health insurance through their employer. This makes workplaces a logical channel for expanding access to medications that carry a significant price tag for many patients.

eMed’s message to employers is direct: covering these drugs offers real value. The benefits work in both directions. Employees gain better health outcomes, and companies can lower long-term costs tied to heart disease and diabetes complications. Brady echoed this point, explaining that the program cuts costs for businesses while genuinely improving employee health.

The situation carries more nuance than it first appears, though. Insurance details often determine whether someone actually receives coverage, including prior authorization rules and formulary restrictions. Medicare has historically declined to cover weight loss prescriptions, even though it covers diabetes medications under separate rules. This gap between insurers is exactly what employer-sponsored programs aim to close.

Supply constraints create another layer of complexity. These medications have faced repeated shortages as demand has outpaced manufacturing capacity. The FDA continues to monitor these shortages closely. One key concern stands out: heavy demand from workplace programs could limit supply for diabetes patients who depend on these same drugs for daily glucose control.

Compounded versions of these medications add further risk. Cheaper alternatives appeared during supply shortages, and the FDA has flagged concerns about inconsistent purity and dosing. Employer programs like eMed’s typically avoid this problem by using only FDA-approved formulations.

Yaccarino says the company wants to bring Brady’s disciplined athletic mindset into workplace health programs. The larger goal centers on reducing chronic disease rates among employees over time.

Nobody can say yet whether this partnership will produce lasting results. Employee adherence to treatment will shape much of that outcome. Coverage generosity will matter too. Regulatory clarity will likely influence how these programs scale in the years ahead.